Navigation

Investiment.io
Financial analysis platform

Pfizer Inc.

PFE β€’ NYSE

$28.91
β–²0.02 (0.05%)β€’ REGULAR

Pfizer Inc.

$28.91
β–²0.1%
πŸ“ŠSummaryπŸ“‹SEC FilingsπŸ‘₯Insider Trading
πŸ“„

PFE Q3 2025 Earnings Call

December 16, 2025 at 01:00 PM

Company
PFE
Quarter
Q3 2025
Date
December 16, 2025 at 01:00 PM
Speakers
2
Word Count
~7,841

Transcript Content

Speaker
I'm going to have to defer the Metsera questions to other analysts, but curious to hear what you say there. I'll just ask a couple more on the commercial side. So one, Vyndamax, obviously you're facing more competition there. Surprised to see the performance, there was a little bit of sequential decline. So maybe you can just comment on the pricing and sort of market share dynamics you're seeing in that space, obviously, with the new competitors. And then similar question on Padcev. Obviously, great data that you shared at ESMO. The commercial uptake for the quarter at least was a little bit less than we thought. So maybe just how you expect the muscle invasive indication, assuming you get that here soon, to impact uptake of that program and kind of drive upside to where the numbers are right now?
Speaker
Sure. Vamil, thanks for the question. So let me start with your question on Vyndamax. And I'll just want to level set a couple of things about Vyndamax, and then I'll talk about the performance in the quarter. So there's obviously new competition in the category, and it's important to note that Vyndamax is still the only ATTR-CM product that has statistically significant reductions in both mortality and CV-related hospitalizations together and as a stand-alone. And it's also the only product where there is a once-daily capsule, placebo-like safety, and near complete TTR stabilization. And we've got 90% access for Vyndamax across the U.S. Now with regards to the quarter, there are a couple of different dynamics that are happening. First of all, we saw very strong demand growth, and that's reinforced by our continued market share leadership, both on a TRx basis, clearly, but also in terms of first-line share. Now that volume growth was offset by two gross-to-net headwinds. One is the IRA manufacturer rebates, which we've talked about before. And the second is what we alluded to last quarter, which is payer contracting that took place in the third quarter. So Vyndamax is performing exactly where we thought it would and consistent with what we guided, and performance continues to reflect strong diagnosis, broad access, improving affordability dynamics, and that's going to continue to grow our volume. We are seeing competition that is taking some first-line share from treatment-naive patients, and that has driven minimal switching to date. And as we kind of look forward on Vyndamax, we'll see some of these dynamics continue into Q4 as well, where we expect continued volume growth, but the two GTN drivers that I described will certainly impact our net sales, but Vyndamax is performing in the way that we expected. On your question with regards to Padcev, we're, again, very encouraged by how Padcev is doing. For us, we look at this through two lenses. First is the a/mUC population, where we currently have about 55% share among cisplatin-ineligible patients and 45% to 50% share among cisplatin-eligible patients. So there is headroom for us to continue to focus on that segment of the market. I think your question with regards to how Padcev performed on consensus is related to the comment that Dave made, which is as part of integrating the Seagen products into the Pfizer portfolio in Q2, we moved from a drop ship model to a wholesaler model. So that resulted in a one-time growth in our Q2 sales. So you have to grow products off of that adjusted for two to three weeks of inventory. So as we cycle into Q4, we expect the whole Seagen portfolio, including Padcev, to return to growth. And then finally, on MIBC, we're excited about the possibilities as a result of both the 303 and 304 trials that are ongoing, and that will open up a patient population of close to 22,000 patients to help with the next rise of Padcev growth.
Speaker
Congrats on the performance in the quarter. So my question is on Metsera. Could you just comment on the legal process ahead? I know that Pfizer is arguing that Novo's acquisition of Metsera would be anticompetitive. And even if the FTC doesn't allow it, it could be anticompetitive. So could you just talk us through the clock and the process for courts to hear Pfizer's arguments? Albert Bourla (Chairman): Thank you, Dave. As I said in my opening comments, it is very difficult for us to start commenting when we have all these legal issues pending. But I will repeat what I did say, which is kind of an answer to your question, not on the timing, but we don't see how Novo's deal can be superior. It is an illegal attempt by a foreign company to do an end run around antitrust laws, taking advantage of the government shutdown. What they want to achieve is not to get the products, but to destroy them. What they want is to catch and kill an emerging competitor, which is a significant antitrust concern given Novo's dominant market position. So all I can say to this is that we are continuing to pursue all legal resources. Thank you. Next question, please.
Speaker
I guess just for Albert and Dave, just a quick high-level question on BD. What's the plan if Metsera doesn't work out for some reason? And then second, on 2026, any early framing on guidance pushes and pulls, specifically on how we should think about OpEx with and without Metsera? And then any additional color on how to think about the dilution you mentioned from your recent MFN deal with the administration? David Denton (CFO): Yes. So maybe we'll start with business development. Obviously, the company has still significant resources to understand and how to deploy successfully transactions to bring science in-house, and we will continue to work aggressively to do so across all of our 4 therapeutic areas, and we continue to work across the globe to identify potential candidates for acquisition to help bring new and innovative medicines to patients. So that's still a very ongoing focused activity for the company. I think it's probably a little early to talk exactly about 2026. You heard me give a little color in the sense that clearly, we're making investments today and those investments carry over into '26 and beyond, with either Metsera or 3SBio to bring these innovative medicines to market. Those will have a slightly dilutive effect on our operating performance next year. We will then wrap all that together with the puts and takes of '26 when we give guidance by the end of this year. Albert Bourla (Chairman): Anything to add on BD, Andrew?
Speaker
Yes. I mean I'd echo what Dave said that we are very active in all geographies, especially in China. You saw the 3SBio, which has a foundational asset to become the backbone across multiple indications. And the same is true in China and beyond across all the main therapeutic areas. We've increased the size of our team in China, in particular, and we have very active efforts. And when we have something to inform you, you'll certainly be the first to know.
Speaker
I guess one for Albert or Dave. When you look at the manufacturing investments you're making as part of the MFN agreement relative to the operational cost efficiencies, how would you rank those as priorities? I guess, both seem to have 3-year time frames. I'm just trying to get a sense of the incremental dollar and the strategy there. David Denton (CFO): Yes. Clearly, there are important elements of our strategy. We're going to clearly invest in the U.S. from a production perspective. We're working now to work through our plans with the new agreement with the U.S. government on how to effectively deploy our capacity here in the U.S. and further build it out. More to come. We will also provide some color to that when we give guidance for 2026. But we will be able to improve our manufacturing operating infrastructure and at the same time invest in manufacturing here in the U.S. And those two are not necessarily completely in conflict with one another. We'll be able to do both.
Speaker
Thank you so much for answering our questions today. I really wanted to understand and perhaps have another question on the net zero, but from a different angle. I wanted to understand, in your mind, what factors supported Pfizer in garnering that unprecedented early termination of the waiting period from the U.S. Federal Trade Commission. That would be really helpful. Albert Bourla (Chairman): I'm not sure I understood the question. Francesca DeMartino (Head of Investor Relations): The FTC clearance. Albert Bourla (Chairman): I believe the FTC made its own decision regarding our deal. They were certainly aware of this issue, but I don't want to speak on their behalf. They determined that it was appropriate to proceed with our deal during a foreign attempt, which is now clear. David Denton (CFO): I think it does further demonstrate the strength of our deal and the pathway to clearance and the pathway for us to be able to further develop these products and take them to the marketplace in a very rapid fashion. This is helpful to patients long-term; it's helpful to prices long-term under our management and our direction with these assets. Albert Bourla (Chairman): Yes, we shouldn't be surprised because this situation exemplifies a significant antitrust issue. Metsera's entire pipeline reflects Novo's entire pipeline, and they hold a dominant position with their existing products. Naturally, the FTC would have concerns about this. I won't presume to speak on their behalf, but it's something that everyone is aware of. Next question, please.
Speaker
Maybe two for me. You've previously talked about Elrexfio being a key driver for you over the long term. We noticed that MagnetisMM-5 trial was pushed out data into 2026. We know J&J had a similar trial in a similar patient population that just read out. So maybe you could just remind us of any potential differences here in terms of your trial versus their trial and why there might be a difference in timing given they started around the same time? And the second question is just a clarification on Paxlovid dynamics for the quarter. It looks like by our math, price per script went up over last quarter. So just wondering if there's any one-time items that we need to think about here as we think about the trends in the fourth quarter.
Speaker
Yes, thanks for the question. So MagnetisMM-5, as you know, is a double class exposed event-driven study. Timing could shift due to events not happening, which we cannot speculate. But as you can imagine, that's often positive if events are not happening in the study. So we'll just continue to follow the events and hopefully report early next year. David Denton (CFO): Yes. And on the Paxlovid question, I don't think there's any material change in price. We have maybe there's different channels mix and things of that nature, but nothing significant from that standpoint.
Speaker
I had a question on your upcoming Phase III EZH2 readout in CRPC. I'm surprised the study is more prominently flagged given the potential to extend the XTANDI franchise. What drives your confidence that you're getting adequate target exposure after examining some of your food effect studies? And also, what's your expectations around overall survival? Could we see a 20% to 30% benefit here? Albert Bourla (Chairman): Chris, that's for you.
Speaker
Thank you very much for the question. This is another first-in-class internally discovered program, the EZH2 program. We've previously shared randomized data, which showed significant PFS benefit in all comers in late-line metastatic castration-resistant prostate cancer. We now have three Phase III studies ongoing. The first one will read out, to your point, is post-abiraterone metastatic hormone-resistant prostate cancer, and that we expect in the coming months. We recently also presented data at ASCO, randomized data on the food effect to your question, which was 875 milligrams twice a day with food and showed that the data are comparable with the dose we now use in Phase III with reduced GI AE. So we are confident in the dose that was selected.
Speaker
Just on the guidance for this year, you've clearly reiterated the total revenue range of $61 to $64, but when you first set that guidance, you spoke of total COVID-19 sales of around $9 billion for the year, seeing that you booked only around just over $4 billion year-to-date. Just interested in your comments on whether that $9 billion is still achievable for the full year? And if not, what other assets would you call out as likely to fill that gap and give you confidence to reiterate the total sales guidance? Albert Bourla (Chairman): Thank you. Dave, please? David Denton (CFO): Yes. You're correct, Kerry. I would say that the lower end of our revenue guidance assumes a very modest uptake of the COVID franchise for the rest of this year, especially in the U.S. However, the COVID franchise can experience fluctuations. If we encounter a COVID wave in the coming months, utilization could increase significantly. That’s why our range is quite broad. Additionally, we have mitigated risks with our earnings per share guidance for the COVID franchise, indicating that if current trends persist, we will be nearer to the lower end of that range, while still meeting our earnings commitment.
Speaker
I would like to understand the reasoning behind the pricing of GLP-1 and this class of medications, especially since there is a news article suggesting the price could be around $150. It appears that the price is only decreasing. In that context, how do you justify the price you are paying to Metsera, and how do you view the obesity market over time considering this decline in pricing for the class? Albert Bourla (Chairman): Yes. Thank you. This is also competition that brings prices down. And of course, they try not to restrict competition. But anyway, yes, we, in our calculations, have taken into consideration that the prices of GLP-1s probably will start going down. So I don't know what will be announced now. But in our calculations, we took already that into consideration.
Speaker
Can you elaborate more on the reason for the delay to the initiation of the pivotal trial for the adult 25-valent pneumococcal program? You had mentioned the caveat of if the FDA aligns with your approach. So the tenor of the dialogue change with the FDA? Is there a chance that surrogate endpoints may no longer be approvable?
Speaker
Yes. Thank you for the question. Across all our vaccine programs, we're obviously working very closely with the FDA and other regulators on the designs of the study and also the endpoints. PCV25, pending positive data and FDA feedback, we intend to start that study as well as the pediatric 25-valent program next year. So it means we will align the pediatric and the adult study. We expect the fourth dose data from the pediatric study early next year. So that helps us to coordinate the 2 studies. The 25 vaccine candidate covers 25 serotypes, particularly I need to point out serotype 3, which we did before because the vaccine is designed with significantly enhanced immunogenicity against serotype 3, which currently constitutes up to 20% of infections in the U.S. and the EU. To continue our leadership, we also continue to study our fifth generation with 30-plus serotypes, which we'll update you on more in 2026. Albert Bourla (Chairman): Thank you, Chris. Operator, the next question please.
Speaker
Just maybe two MFN questions. First one is kind of bigger picture. As you think about MFN on new launches over time, what do you think about this suggesting for international revenues? Is this, I guess, I could read this as a net positive that you can get higher price? I can read as net negative because reimbursement hurdle is going to be tougher at these higher prices; it could be neutral. Just how you kind of envisioned what plays out with international as you signed that deal? And then the second one is just trying to get a little bit more color on the MFN impact for 2026. I think you mentioned some dilution there, but just any more quantitative metrics you could provide of just how much of a headwind is that for next year? Albert Bourla (Chairman): Yes. I apologize for having to ask Dave to elaborate, but he will. We will provide guidance at the end of the year, which will include everything, including what he mentioned. I don't think we will have much more to say regardless of how much you inquire. Regarding new launches internationally, we are waiting to see how things unfold. The price difference is not sustainable. We are discussing a limited number of countries internationally that are impacted by this. We hope these countries will recognize the need to adjust their pricing strategies moving forward. A bit of assistance from the U.S. government and USTR through trade negotiations could facilitate this change. My view is that the U.S. Trade Representatives are extremely committed to resolving this issue. We will see how it progresses. Ideally, if we cannot agree on a reasonable pricing model, we will not receive reimbursement in those regions, and we will adjust prices to avoid impacting U.S. pricing. Thank you. Let's move to the next question, please.
Speaker
First, on Metsera, I realize this is perhaps in the hands of your M&A lawyers and antitrust lawyers. But from an R&D perspective, can we make sure you'll be evaluating all the new data that's imminent, for example, the monthly transition and how the GI tolerability holds as well as even more importantly, the amylin plus GLP early combo data? And then separately, I was very intrigued by a Phase IIb trial you guys initiated on an oral drug in atopic dermatitis. Could you confirm if it's a STAT6 inhibitor? And were you able to gauge the magnitude of STAT6 inhibition Phase I? Albert Bourla (Chairman): On the Metsera, it's straightforward; if they share data or make it public, we are looking forward to seeing it and believe it will be positive. For the second question, I will ask Chris to provide his input.
Speaker
Thank you, Umer, to ask a question regarding our I&I portfolio. I just want to check, are you referring to PF9820? Albert Bourla (Chairman): I don't think he can come back in.
Speaker
It is, okay. So you are correct. That is a STAT inhibitor. I want to point out that we currently have a very differentiated I&I portfolio with at least 5 molecules in-house discovered and developed, most of these at a significantly accelerated speed, including obviously p40/TL1a, which is being co-developed with Roche, which covers IL-12 and IL-23 by p40. Our 2 tri-specifics covering IL-4, IL-13, TSLP, or IL-33, both of those now entering Phase II for atopic dermatitis and for other Th2-related diseases. Litfulo with the ongoing and Phase III trial in non-segmental vitiligo, which is a JAK3/TEC inhibitor, also differentiated in-house. And then the STAT6 early, just entering Phase II, could be potentially first-in-class oral. We're currently further optimizing dose and formulation and hope to update you on that program in 2026. Albert Bourla (Chairman): Thank you very much, next question please.
Speaker
Two questions. What does the drug pricing deal with the administration allow Pfizer to do that other companies will not be able to do other than, of course, AstraZeneca? And secondly, on Metsera, so the data looks more similar than different than competitors, and Metsera disclosures haven't been completely transparent, raising serious questions. Many other big-cap pharmas have passed over Metsera when pursuing other products, validating the me-too point. Nothing in all this justifies a bidding war or even a protracted legal battle. Is Pfizer's determination to persist underpinned by substantial confidential data or simply the desire to be a player in obesity? Or does Pfizer agree with the points that I just said and could it just walk away? Albert Bourla (Chairman): Thank you for the question regarding drug prices and our advantages compared to other companies. I cannot comment on what other companies are experiencing, as discussions occur between the administration and individual companies, ensuring there are no antitrust concerns. Additionally, confidentiality is a crucial aspect of these discussions and agreements, limiting what can be disclosed. I can share that we have some public information and aspects of a broader deal, but I cannot speculate on what others will achieve. Regarding Metsera, we have reviewed the data thoroughly and set a price that we believe offers significant value to both Metsera and Pfizer's shareholders. We believe having these assets will give us a strong competitive advantage. Currently, there is an ongoing effort to undermine Pfizer as a competitor, aiming to gain control of the company while avoiding antitrust scrutiny by becoming the primary shareholder and creditor without regulatory oversight. That sums up my thoughts, and we will see how things unfold.
Speaker
Assuming Metsera closes, what near-term factors must you consider to continue growing the dividend, and then delevering, Dave, as you had said, when do you think you may be able to also start to repurchase shares? Or is that less of a priority with all this BD? David Denton (CFO): Evan, that’s a great question. Over the past one and a half to two years, we have focused heavily on improving productivity across our platform. This improvement has helped us decrease our leverage from about 4x to 2.7x, giving us more flexibility for business development and to both maintain and grow our dividend over time. We have integrated this cycle of productivity improvement into the company and will continue to apply it across the enterprise. We are prioritizing our research and development efforts, particularly on key assets we believe will drive our growth by the end of the decade. We plan to invest in these assets and in the product categories we have acquired or recently launched, as these will help us counteract losses over the next few years. Additionally, share repurchases are an important option for us, but in the short term, we won’t be utilizing this tool. We need to strengthen our balance sheet first, as there are business priorities that take precedence right now. Thank you for the insightful question. Albert Bourla (Chairman): Okay. So now I think let's get the last question.
Speaker
I have two questions, if I may. I understand you cannot provide much detail about Metsera at this time. From a modeling perspective, if we are considering additional balance sheet capacity for dealmaking, how much capacity would you estimate, assuming you are reserving some capacity away from Metsera in your internal budgeting for 2026? That information would be really helpful. Regarding 3SBio, I know the deal has just closed and some trials have recently started. When can we expect to see data updates from that deal? Will it be more of a 2027 event, or are there any interim readouts or updates expected in 2026? David Denton (CFO): Yes. So as you think about BD capacity, as I said in my prepared remarks, we have approximately $13 billion of capacity as we enter here into the third quarter, so with that...
Speaker
Yes, the data flow. So just a reminder, at ASCO 2025, we shared Phase II monotherapy data in first-line non-small cell lung cancer showing an overall response of 65%. At ESMO, Phase II combination data plus chemotherapy was shown for first-line metastatic colorectal cancer, indicating a response rate of close to 60%. At SITC, we will provide additional combination data in lung cancer, and we have just initiated two Phase III programs this year in first-line non-small cell lung cancer and first-line colorectal cancer. In the coming weeks, we will also present the full development plan at an event, showcasing the breadth and depth of our clinical development program for the 707. Albert Bourla (Chairman): Thank you, Chris. So thank you very much all for your attention. We have been successful in achieving a series of significant strategic milestones. We delivered a solid performance during the quarter, and we are confident in our business, and that's why we are raising the rates of our adjusted diluted EPS. And of course, we maintain our revenue despite the lowest COVID right now trends. So thank you for your interest in Pfizer, and I hope you have a wonderful week.
Operator
This does conclude today's program. Thank you for your participation. You may disconnect at any time.